By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Phenobarbital

Phenobarbital

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
6 Min Read
SHARE
4 min read|758 words

Phenobarbital Drug Profile

What is Phenobarbital?

Phenobarbital is a barbiturate medication that belongs to the class of drugs known as anticonvulsants or antiepileptic drugs. It is one of the oldest and most widely used medications for treating seizure disorders, particularly in developing countries due to its effectiveness and low cost. Phenobarbital is also used as a sedative and in some cases for alcohol withdrawal management.

Uses

Epilepsy and seizure control: Phenobarbital is primarily prescribed for the long-term management of various types of seizures, including generalized tonic-clonic seizures, focal seizures, and febrile seizures in children. It is particularly effective for controlling seizures that don’t respond well to newer anticonvulsants.

Status epilepticus: In emergency situations, phenobarbital may be used intravenously to treat status epilepticus, a life-threatening condition of prolonged or repeated seizures.

Sedation: Phenobarbital can be used as a sedative for patients who require calming before medical procedures or for those with severe anxiety, though this use has largely been replaced by safer alternatives.

Submit Your Paper
GMJ_Submit_Banner

Alcohol withdrawal: The medication may be prescribed to help manage symptoms during alcohol withdrawal, particularly in patients who have a history of withdrawal seizures.

Neonatal seizures: Phenobarbital is often the first-line treatment for seizures in newborns and infants due to its safety profile in this population.

How it works

Phenobarbital works by enhancing the activity of gamma-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. It binds to GABA receptors in the brain and prolongs the opening of chloride channels, which helps to calm overexcited nerve cells and prevent the abnormal electrical activity that causes seizures. This mechanism also produces the sedative effects associated with the medication.

Side effects

Common side effects:

  • Drowsiness and sedation
  • Dizziness and unsteadiness
  • Cognitive impairment and confusion
  • Fatigue and weakness
  • Nausea and vomiting
  • Headache
  • Irritability and mood changes
  • Sleep disturbances

Serious side effects to watch for:

  • Severe allergic reactions including Stevens-Johnson syndrome
  • Respiratory depression, especially when combined with other depressants
  • Severe depression or suicidal thoughts
  • Blood disorders such as anemia or low platelet count
  • Liver damage or hepatitis

Warnings and precautions

Pregnancy considerations: Phenobarbital is classified as a Category D medication during pregnancy, meaning it may cause fetal harm. It can cause birth defects and bleeding problems in newborns, but may still be necessary if the benefits outweigh the risks for seizure control.

Addiction potential: Phenobarbital has significant potential for physical dependence and abuse. Sudden discontinuation can lead to dangerous withdrawal symptoms including seizures, so the medication must be tapered gradually under medical supervision.

Elderly patients: Older adults are more sensitive to phenobarbital’s effects and may experience increased confusion, falls, and cognitive impairment. Lower doses are typically required.

Liver and kidney impairment: Patients with liver or kidney disease may need dose adjustments as these organs are responsible for metabolizing and eliminating the drug from the body.

Respiratory conditions: Phenobarbital should be used with extreme caution in patients with respiratory disorders, as it can suppress breathing, particularly at higher doses.

Interactions

Warfarin and other blood thinners: Phenobarbital can reduce the effectiveness of anticoagulants by increasing their metabolism, potentially requiring dose adjustments.

Oral contraceptives: The medication can decrease the effectiveness of birth control pills by increasing their breakdown in the liver, potentially leading to contraceptive failure.

Other central nervous system depressants: Alcohol, opioids, benzodiazepines, and other sedating medications can dangerously increase drowsiness and respiratory depression when combined with phenobarbital.

Phenytoin and other anticonvulsants: Complex interactions can occur with other seizure medications, requiring careful monitoring and possible dose adjustments.

Corticosteroids: Phenobarbital can increase the metabolism of steroid medications, reducing their effectiveness.

Calcium channel blockers: The medication may reduce the effectiveness of some blood pressure medications by increasing their metabolism.

Vitamin D and folate: Long-term use can interfere with the metabolism of these vitamins, potentially requiring supplementation.

Griseofulvin: Phenobarbital can reduce the effectiveness of this antifungal medication.

Check interactions with the GMJ Interaction Checker

Dosage

Adult dosages vary significantly based on the condition being treated and individual patient factors. For epilepsy, typical starting doses range from 60-100 mg daily, which may be gradually increased to 100-300 mg daily depending on seizure control and tolerance. For sedation, much lower doses of 30-120 mg may be used. Doses are usually divided throughout the day or given as a single bedtime dose. All dosing must be individualized and determined by a healthcare provider based on blood levels, seizure control, and side effect profile.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Phenobarbital." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/phenobarbital/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy

New genetic testing could spare 6,600 UK breast cancer patients annually from…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Leflunomide

By
Prof. Giorgi Pkhakadze
02/06/2026

Calcium supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Copper supplements

By
Prof. Giorgi Pkhakadze
02/06/2026

Pioglitazone

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up